John Coombs

1.7k total citations
45 papers, 1.4k citations indexed

About

John Coombs is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Coombs has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 12 papers in Genetics and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Coombs's work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Gastrointestinal Tumor Research and Treatment (8 papers). John Coombs is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Gastrointestinal Tumor Research and Treatment (8 papers). John Coombs collaborates with scholars based in United States, France and Switzerland. John Coombs's co-authors include Samuel H. Zwillich, Mark P. Fletcher, Joel M. Kremer, Bradley J. Bloom, Bethanie Wilkinson, Cristiano A. F. Zerbini, David Gruben, Sriram Krishnaswami, Ferdinand C. Breedveld and Rubén Burgos‐Vargas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

John Coombs

45 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Coombs United States 17 493 373 309 289 198 45 1.4k
Arijit Ganguli United States 22 439 0.9× 191 0.5× 83 0.3× 126 0.4× 360 1.8× 90 1.4k
Weiwei Feng China 18 85 0.2× 220 0.6× 208 0.7× 240 0.8× 54 0.3× 38 1.3k
Shreekant Parasuraman United States 20 338 0.7× 400 1.1× 416 1.3× 84 0.3× 55 0.3× 68 974
Keith A. Betts United States 23 366 0.7× 326 0.9× 110 0.4× 328 1.1× 582 2.9× 129 2.0k
Valerie Nell Austria 15 2.4k 4.8× 919 2.5× 355 1.1× 129 0.4× 361 1.8× 20 2.8k
L. van Tuyl Netherlands 23 1.1k 2.3× 398 1.1× 142 0.5× 127 0.4× 172 0.9× 75 1.6k
Kathleen Tymms Australia 18 429 0.9× 158 0.4× 104 0.3× 36 0.1× 136 0.7× 51 1.1k
P L van Riel Netherlands 10 1.3k 2.6× 544 1.5× 178 0.6× 84 0.3× 189 1.0× 10 1.5k
Carolyn Neville Canada 20 961 1.9× 311 0.8× 89 0.3× 89 0.3× 362 1.8× 40 1.3k
Peter Tsao United States 11 798 1.6× 159 0.4× 86 0.3× 83 0.3× 215 1.1× 12 1.1k

Countries citing papers authored by John Coombs

Since Specialization
Citations

This map shows the geographic impact of John Coombs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Coombs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Coombs more than expected).

Fields of papers citing papers by John Coombs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Coombs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Coombs. The network helps show where John Coombs may publish in the future.

Co-authorship network of co-authors of John Coombs

This figure shows the co-authorship network connecting the top 25 collaborators of John Coombs. A scholar is included among the top collaborators of John Coombs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Coombs. John Coombs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Parthan, Anju, et al.. (2013). Comparison of Different Adjuvant Therapies for 9 Resectable Cancer Types. Postgraduate Medicine. 125(2). 83–91. 1 indexed citations
2.
3.
Coombs, John, et al.. (2012). Experiences and perspectives on the GIST patient journey. Patient Preference and Adherence. 6. 653–653. 18 indexed citations
4.
Marín, Mar, et al.. (2012). PSY19 Burden of Illness (BOI) of FLT3-Mutated Acute Myeloid Leukemia (AML). Value in Health. 15(4). A101–A102. 4 indexed citations
5.
Coombs, John, et al.. (2012). PSY23 Burden of Illness of Aggressive Systemic Mastocytosis (ASM) in the United States. Value in Health. 15(4). A102–A102. 1 indexed citations
6.
Taylor, Douglas C.A., et al.. (2012). Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. Journal of Medical Economics. 16(1). 150–159. 18 indexed citations
7.
Gater, Adam, Louise Heron, Linda Abetz‐Webb, et al.. (2012). Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leukemia Research. 36(7). 817–825. 49 indexed citations
8.
Parthan, Anju, et al.. (2012). PCN27 Clinical Benefit and Economic Impact of Three-Years of Adjuvant Imatinib in KIT+ Gastrointestinal Stromal Tumors (GIST). Value in Health. 15(4). A212–A212. 1 indexed citations
9.
Guest, Julian F., et al.. (2011). Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leukemia & lymphoma. 53(5). 928–933. 7 indexed citations
10.
Beaumont, Jennifer L., Cindy J. Nowinski, John Coombs, et al.. (2011). Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?. Blood. 118(21). 1025–1025. 1 indexed citations
11.
Spencer, David H., Vamsi Bollu, Benjamin Chastek, et al.. (2011). Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib.. Journal of Clinical Oncology. 29(15_suppl). e16612–e16612. 1 indexed citations
12.
Taylor, Douglas C.A., et al.. (2010). Budgetary Impact of Treatment with Adjuvant Imatinib for 1 Year Following Surgical Resection of Kit-Positive Localized Gastrointestinal Stromal Tumors. Journal of Managed Care Pharmacy. 16(7). 482–491. 8 indexed citations
13.
14.
15.
Kremer, Joel M., Bradley J. Bloom, Ferdinand C. Breedveld, et al.. (2009). The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo. Arthritis & Rheumatism. 60(7). 1895–1905. 440 indexed citations
16.
Simon, Lee S., Christopher J. Evans, Nathaniel P. Katz, et al.. (2007). Preliminary development of a responder index for chronic low back pain.. PubMed. 34(6). 1386–91. 29 indexed citations
17.
Coombs, John, et al.. (2007). (899). Journal of Pain. 8(4). S75–S75. 1 indexed citations
18.
Johnson, F. Reed, Brett Hauber, David Osoba, et al.. (2006). Are Chemotherapy Patients’ HRQoL Importance Weights Consistent with Linear Scoring Rules? A Stated-choice Approach. Quality of Life Research. 15(2). 285–298. 40 indexed citations
19.
Osoba, David, Ming‐Ann Hsu, Catherine Copley‐Merriman, et al.. (2006). Stated Preferences of Patients with Cancer for Health-related Quality-of-life (HRQOL) Domains During Treatment. Quality of Life Research. 15(2). 273–283. 58 indexed citations
20.
Abetz, Linda, et al.. (2005). Development of the Cancer Therapy Satisfaction Questionnaire: Item Generation and Content Validity Testing. Value in Health. 8. S41–S53. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arijit Ganguli Breakdown of academic impact, for papers by Weiwei Feng Breakdown of academic impact, for papers by Shreekant Parasuraman Breakdown of academic impact, for papers by Keith A. Betts Breakdown of academic impact, for papers by Valerie Nell Breakdown of academic impact, for papers by L. van Tuyl Breakdown of academic impact, for papers by Kathleen Tymms Breakdown of academic impact, for papers by P L van Riel Breakdown of academic impact, for papers by Carolyn Neville Breakdown of academic impact, for papers by Peter Tsao
Rankless by CCL
2026